Key Highlights
- Shares of Butterfly Network climbed approximately 31% following Midjourney’s reveal of its healthcare arm, Midjourney Medical, alongside the Midjourney Scanner device
- Each prototype of the full-body ultrasonic scanner incorporates 40 Ultrasound-on-Chip modules from Butterfly, part of a collaboration valued at up to $74 million spanning five years
- TD Cowen’s Joshua Jennings noted the partnership proves Butterfly’s chip-licensing model can function as an independent revenue source
- Midjourney’s ambitious rollout targets 5,000 scanner spa facilities and more than 50,000 deployed units worldwide by 2031, potentially driving substantial chip orders for Butterfly
- William Blair raised concerns regarding FDA clearance timelines, insurance coverage, and the proven clinical benefit of regular full-body scanning
Shares of Butterfly Network (BFLY) climbed to $7.54 on Thursday, marking roughly a 31% increase, after Midjourney publicly introduced its healthcare initiative featuring technology centered on Butterfly’s proprietary innovations.
Midjourney Medical introduced the Midjourney Scanner — a comprehensive ultrasonic computational tomography system designed for full-body imaging. Each existing prototype integrates 40 Ultrasound-on-Chip imaging modules manufactured by Butterfly. Upcoming iterations are anticipated to incorporate even more modules.
The revelation propelled BFLY to reach a fresh 52-week peak of $8.01 during trading hours, climbing from the previous closing price of $5.71.
This collaboration operates through Butterfly Embedded, previously called Octiv — the division responsible for chip licensing and joint development initiatives. Butterfly revealed the partnership details in an SEC document filed in November 2025, indicating anticipated payments totaling up to $74 million across a five-year period.
Elon Musk responded to the news on X with a brief “cool,” which helped maintain social media buzz around the development throughout trading hours.
Short interest stood at approximately 12.6% of available shares going into Thursday. The unwinding of these short positions contributed additional momentum to the stock’s upward movement.
Analyst Perspectives
Joshua Jennings from TD Cowen was prompt in emphasizing the strategic significance. He contended the collaboration demonstrates that Butterfly’s chip technology holds substantial value independent of its portable ultrasound product line — creating pathways for licensing income, future semiconductor sales, and shared revenue arrangements.
William Blair also provided commentary, identifying Midjourney’s deployment strategy as a potentially significant long-term growth catalyst for Butterfly.
Midjourney aims to establish 5,000 specialized “Midjourney Spas,” with each facility operating approximately 10 scanning devices. The inaugural location is projected to launch in San Francisco during late 2027.
The organization is simultaneously developing next-generation scanning equipment scheduled for 2028, with objectives to deploy over 50,000 units internationally by 2031. With roughly 40 chips required per scanner, William Blair suggested this calculation represents a meaningful revenue opportunity for Butterfly’s semiconductor division.
Unanswered Questions Persist
Not all observers are entirely convinced. Andrew Brackmann from William Blair identified several outstanding concerns that may influence the partnership’s ultimate success.
He questioned Midjourney’s ability to secure FDA authorization quickly enough to accommodate such aggressive demand projections. Insurance reimbursement presents another significant obstacle — Brackmann views it as essential to realizing the market potential.
He additionally observed that no preliminary clinical data from the scanner currently exists to demonstrate meaningful benefits for routine full-body screening applications.
Butterfly’s leadership team, including CEO Joe DeVivo, CFO John Doherty, and SVP of Innovation David Horsley, were set to participate in a TD Cowen Medical Devices Emerging Growth conference call at noon ET on Thursday.
The overall market environment was favorable as well, with the S&P 500 gaining 0.9% and the Nasdaq advancing 1.2% during the trading session.
BFLY was changing hands at $7.49, reflecting a 31.1% increase, at the time of publication.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
